24 Mar, 2026 Alnylam TTR Investor Webinar 2026

On March 24, 2026, we hosted a TTR investor webinar to highlight Alnylam’s progress in delivering for patients with ATTR-CM, as well as the long-term growth and durability of the Company’s flagship TTR franchise. The event included presentations from Alnylam’s senior commercial and medical leaders.

To view the webcast, click here
To view the presentation, click here

Speakers:

Tolga Tanguler, Chief Commercial Officer
Tolga Tanguler is Chief Commercial Officer at Alnylam Pharmaceuticals, where he leads the company’s global commercial organization, including sales, marketing, market access, patient services, government affairs, and customer-facing digital and technology platforms. He brings more than two decades of experience leading biopharmaceutical companies, with a track record of building and scaling high-performing organizations across the U.S., Europe, Japan, and emerging markets

Prior to Alnylam, Tolga served as Head of Alexion U.S. He spent the majority of his career at Pfizer, where he held a series of senior leadership roles, including President, North America Rare Diseases. His experience spans global brand leadership and regional business management, including work on some of the industry’s most recognized medicines, such as Ultomiris, Eliquis, and Viagra.

Tolga’s experience includes large-scale primary care, specialty therapeutics, and rare diseases, positioning him as a global executive with end-to-end expertise across the biopharmaceutical value chain. He has led enterprise-wide digital and omnichannel transformation to modernize customer engagement and commercial execution. Tolga is a member of the Board of Directors of the Biotechnology Innovation Organization (BIO) and serves as co-chair of BIO’s Policy & Access to Medicines Committee, helping shape industry policy and access frameworks. He is also a member of the Board of Directors of Lexeo Therapeutics, a clinical stage genetic medicine company.

Tolga holds a B.S. in Finance and Economics from Istanbul University, an MBA from Michigan State University, and a postgraduate certificate in Marketing from the University of California, Santa Barbara.

John Kennedy – SVP, TTR Franchise Global Commercialization Lead
John Kennedy is Senior Vice President, TTR Franchise Global Commercialization Lead. John brings 30 years of experience spanning general management, a range of in-country and global commercial roles, as well as a background in regulatory affairs supporting pre- and post-approval programs.

Prior to joining Alnylam, John was with Alexion/AZ Rare Diseases, where he was Vice President and Business Unit Lead for the US Rare Hematology & Nephrology Disease Franchise. In that role, John led business unit strategy, oversaw cross-functional operations and was accountable for financial performance. He oversaw the US launch of what is now a multi-indication flagship brand for Alexion including lifecycle and commercial model evolution, enabling sustained leadership in an evolving competitive landscape.

Prior to Alexion, John spent 20 years at Pfizer where he served in general management roles (Country Manager, Business Unit Lead) and various leadership roles across Marketing, Sales and Account Management. John rose to commercial leadership roles after progressing through a series of global and in-country marketing positions supporting brands including Lipitor (in both US and Global Marketing organizations) within the cardiovascular space, amongst others. Before moving into these commercial roles, John served as a Director of Worldwide Regulatory Strategy with responsibility for pre- and post-approval programs across a range of therapeutic areas.

Before Pfizer, John worked in the medical device industry. He holds an M.B.A. from NYU’s Stern School of Management, and a Bachelor of Science in Biology from Fairfield University.

Mark Soued – SVP, Head of U.S. & TTR Lead
Mark Soued is currently the Senior Vice President, Head of US & TTR Lead at Alnylam. Prior to Alnylam, Mark spent almost 21 years at Pfizer. In his final role before joining Alnylam he served as the Regional President for Pfizer’s North America Hospital Business Unit with responsibility for leading an organization representing ~400 colleagues, >150 products, and generating ~$3B in annual revenues. In this role he also led the negotiation that secured a $5.3B US government contract to purchase 10M courses of Pfizer’s new COVID antiviral, PAXLOVID. Prior to this, Mark served as Pfizer’s Vice President, Global Rare Cardiology Franchise Lead, with responsibility for building a rare cardiology franchise with Vyndaqel/Vyndamax (tafamidis) at its core. Preceding this, Mark served as Pfizer’s US Marketing Lead for Vyndaqel/Vyndamax, where he led the highly successful US launch of the brands that exceeded both Pfizer and Wall Street expectations.

During his time with Pfizer, Mark held multiple additional roles including Oncology Business Unit Lead for Northwestern Europe overseeing Pfizer’s overall oncology business in the Netherlands and Nordics, and Asia-Pacific Regional Marketing Lead with responsibility for launching and growing Pfizer’s oncology portfolio across 13 markets. Mark also served as the Director of Business Operations and Strategy for Pfizer’s Specialty & Oncology Commercial Unit, where he was involved in a broad range of strategic/operational initiatives for the Oncology, Inflammation, Anti-Infectives, and Rare Diseases portfolios. Additionally, Mark held various US marketing roles in neuroscience and anti-infectives, as well as early roles in Corporate Finance.

Before Pfizer, Mark worked in technology and manufacturing, and also founded a technology startup. Mark holds an M.B.A. from the Kellogg School of Management, and a Bachelor of Science in Finance from the University of Colorado. He currently lives in Boston and New York City with his wife, Deb.

Sameer Bansilal, MD, MS, FACC – VP, TTR Disease Area Lead
Dr. Sameer Bansilal currently serves as Vice President, Global Medical Affairs and TTR Disease Area Head at Alnylam Pharmaceuticals, where he leads enterprise medical strategy for the multi-asset transthyretin (TTR) franchise across cardiomyopathy and hereditary polyneuropathy.

Prior to Alnylam, Dr. Bansilal served as Vice President, Cardiovascular – US Medical Affairs at Bayer, where he led medical strategy across thrombosis, heart failure, and renal portfolios. He represented the U.S. on global product governance teams and contributed to global portfolio prioritization and launch excellence strategy for key cardiovascular assets including Kerendia, Adempas, and asundexian. Dr. Bansilal also played a medical leadership role in managing Bayer’s Cell and Gene Therapy assets and partnered closely with business development organization on key deals for Bayer.

Earlier in his career, Dr. Bansilal was an academic cardiologist and clinical trial leader who trained and worked at Mount Sinai, NY and the TIMI Study Group at Harvard Medical School. He has authored more than 80 peer-reviewed publications, including work published in NEJM, Lancet, JAMA, JACC, and Circulation, and has served on steering committees for landmark global cardiovascular trials. Dr. Bansilal continues to serve patients as a practicing cardiologist at the VA hospital in the Bronx. Dr. Bansilal is board certified in Cardiology and holds a master’s degree in clinical research methodology.

Christine Akinc – Chief Corporate Communications Officer
Christine Akinc joined Alnylam in 2015 as Vice President, Investor Relations & Corporate Communications, was promoted to Senior Vice President, Investor Relations & Corporate Communications in 2019, and was promoted to Chief Corporate Communications Officer in 2024. Christine leads a multidisciplinary team responsible for external & internal communications, corporate responsibility, brand and creative and investor relations. During her time at Alnylam, she has helped scale the company globally, launched 5 products in 4 years, and contributed to building its award-winning culture.

Before joining Alnylam, Christine served as Senior Director, Corporate Communications at Pfizer where she supported internal and external communications for R&D, and also served in various roles in media relations. Before her time at Pfizer, she led corporate media relations for Amgen, supporting executive, tax, litigation, finance and M&A. In her prior role at Amgen, she led communications for the oncology therapeutics franchise and led launch communications for XGEVA and VECTIBIX. Prior to joining Amgen, she worked at FleishmanHillard, a public relations firm, supporting various pharmaceutical and biotech clients, and she started her career in the communications group of Millennium Pharmaceuticals, where she helped launch VELCADE.

Christine received a Bachelor of Arts from Northeastern University. She is a member of the Board of Directors of Invivyd, Inc., a clinical-stage biopharmaceutical company.

Agenda: